Gonadotropin-releasing hormone blockers and cardiovascular disease risk: Analysis of prospective clinical trials of degarelix

Journal of Urology

Volumn 186, Issue 5, 2011, Pages 1835-1842

  Smith, Matthew R ^a   Klotz, Laurence ^b   Van Der Meulen, Egbert ^c   Colli, Enrico ^c   Tankó, László B ^c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Ferring Pharmaceuticals AS   (Denmark)

Author keywords

cardiovascular diseases; GnRH; prostate; prostatic neoplasms; risk

Indexed keywords

CHOLESTEROL; DEGARELIX; TESTOSTERONE; ACETYL-2-NAPHTHYLALANYL-3-CHLOROPHENYLALANYL-1-OXOHEXADECYL-SERYL-4-AMINOPHENYLALANYL(HYDROOROTYL)-4-AMINOPHENYLALANYL(CARBAMOYL)-LEUCYL-ILYS-PROLYL-ALANINAMIDE; GONADORELIN; OLIGOPEPTIDE;

AGE; AGED; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ANDROGEN DEPRIVATION THERAPY; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; BODY MASS; CANCER HORMONE THERAPY; CANCER PATIENT; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG DOSE REGIMEN; ELECTROCORTICOGRAPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COMORBIDITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; VERY ELDERLY;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COMORBIDITY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TESTOSTERONE;

EID: 80053932202     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.07.035     Document Type: Article

References (27)

1. H. Van Poppel, and S. Nilsson Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 71 2008 1001
2. M.S. Cookson, and M.F. Sarosdy Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation South Med J 87 1994 1
3. H. Isbarn, L. Boccon-Gibod, and P.R. Carroll Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks Eur Urol 55 2009 62
4. G.N. Levine, A.V. D'Amico, and P. Berger Androgen-deprivation therapy in prostate cancer and cardiovascular risk American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association Circulation 121 2010 833
5. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448
6. C.S. Saigal, J.L. Gore, and T.L. Krupski Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493
7. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420
8. H.K. Tsai, A.V. D'Amico, and N. Sadetsky Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516
9. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer Cancer 113 2008 3290
10. N.L. Keating, A.J. O'Malley, and S.J. Freedland Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39
11. S.M. Alibhai, M. Duong-Hua, and R. Sutradhar Impact of androgen deprivation therapy on cardiovascular disease and diabetes J Clin Oncol 27 2009 3452
12. M. Roach III, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 2008 585
13. U.E. Studer, P. Whelan, and W. Albrecht Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 2006 1868
14. FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm Accessed August 5, 2011
15. L. Klotz, L. Boccon-Gibod, and N.D. Shore The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 2008 1531
16. N.R. Zinner, M. Bidair, and A. Centeno Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial Urology 64 2004 1177
17. H.F. Chen, E.B. Jeung, and M. Stephenson Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro J Clin Endocrinol Metab 84 1999 743
18. F. Tanriverdi, D. Gonzalez-Martinez, and Y. Hu GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males Clin Exp Immunol 142 2005 103
19. R. Businaro, M. Digregorio, and R. Rigan Morphological analysis of cell subpopulations within carotid atherosclerotic plaques Ital J Anat Embryol 110 suppl 2005 109
20. W.H. Lee, Y.H. Ko, and D.I. Kim Prevalence of foam cells and helper-T cells in atherosclerotic plaques of Korean patients with carotid atheroma Korean J Intern Med 15 2000 117
21. A. Abbate, R. Bussani, and G. Liuzzo Sudden coronary death, fatal acute myocardial infarction and widespread coronary and myocardial inflammation Heart 94 2008 737
22. O.J. de Boer, A.C. van der Wal, and C.E. Verhagen Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques J Pathol 188 1999 174
23. B. Halvorsen, K. Otterdal, and T.B. Dahl Atherosclerotic plaque stabilitywhat determines the fate of a plaque? Prog Cardiovasc Dis 51 2008 183
24. D.Y. Kim, M. Woodroofe, and Y. Wu Testing for a change in the hazard rate with staggered entry Comm Stat Theory Methods 33 2004 2041
25. M.R. Smith, L. Klotz, and B.E. Persson Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer J Urol 184 2010 2313
26. S. Wilson, A. Johnston, and J. Robson Predicting coronary risk in the general populationis it necessary to measure high-density lipoprotein cholesterol? J Cardiovasc Risk 10 2003 137
27. P.J. Saylor, N.L. Keating, and M.R. Smith Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy J Gen Intern Med 24 suppl 2009 S389